Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bionano Genomics Inc. said Friday it has priced an underwritten public offering of 29 million shares at $3.05 a share. The stock closed Thursday at $5.00.

Bionano Genomics prices offering of 29 million shares at discount of $3.05 a share

SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 29,016,393 shares of its common stock at a price to the public of $3.05 per share. The gross proceeds to Bionano from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $88.5 million. In addition, Bionano has granted the underwriters a 30-day option to purchase up to an additional 4,352,458 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares in the proposed offering are to be sold by Bionano. The offering is expected to close on January 12, 2021, subject to customary closing conditions.

Bionano Genomics Announces Pricing of $88.5 Million Underwritten Public Offering of Common Stock

Bionano Genomics Inc. plans to sell more shares after a sudden surge in its stock price in recent weeks, and shares dove in after-hours trading Thursday in response. The company revealed Thursday afternoon that it expects to sell more shares under a shelf prospectus filed in August, but did not spell out how many shares it plans to sell nor at what price.

Bionano Genomics shares fall after plan to sell more stock

Bull markets mature into frenzied displays of greed, hope, and naked euphoria before they die. But that last stage can go on sometimes for years, as we saw in the latter half of the 1990's.

Small Cap Momentum Stocks on the Radar (NASDAQ: BNGO) (OTC US: MMEDF) (OTC US: LVGI) (OTC US: HVBTF)

The stock price of BioNano Genomics Inc (NASDAQ: BNGO) has increased by 156.48% this past week. This is why it happened.

BNGO Stock Price Increased 156.48% This Past Week: Why It Happened

The genetic testing specialist's tools could help to improve care for people with autism.

Why Bionano Genomics Stock Skyrocketed More Than 100% Today

Calithera Biosciences

Calithera Biosciences (NASDAQ: CALA) shares are trading lower after the company announced that its CANTATA study of Telaglenastat in Renal Cell Carcinoma did not achieve its primary endpoint. The company also announced a reduction in workforce by roughly 35%.

Why Calithera, BioNano Genomics And More Are Moving Today

Bionano Genomics (BNGO) stock is taking off on Monday after announcing results from a recent genome study of Autism Spectrum Disorder. The post BNGO Stock Alert: Why Bionano Genomics Stock Is Rocketing Again appeared first on InvestorPlace.

BNGO Stock Alert: Why Bionano Genomics Stock Is Rocketing Again

Shares of BioNano Genomics Inc (NASDAQ: BNGO) have doubled in price through the last two trading days. Before the rally, Bionano Genetics was struggling to maintain the $1-per-share price that is required to be listed on the Nasdaq.

Bionano Genomics Shares Rally On Nasdaq Extension

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that Nasdaq has granted the Company an additional 180-day compliance period, or until June 28, 2021, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement.

Bionano Genomics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by 50.42% as it went from a previous close of $0.88 to $1.33. This is why it happened.

BNGO Stock Price Increased 50.42%: Why It Happened

SAN DIEGO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that Praxis Genomics, LLC received accreditation from the College of American Pathologists (CAP), making it the first CAP-accredited, CLIA-certified diagnostic lab in the United States to offer a laboratory developed test (LDT) based on whole genome analysis with Saphyr. The LDT is designed for postnatal patients suspected of a constitutional genetic disorder. Praxis uses optical genome mapping (OGM) with Bionano's Saphyr System as an alternative to traditional methods of chromosomal microarray (CMA) and karyotyping (KT), as they seek to improve the rate of clinical diagnosis for patients with genetic disease. CMA and KT together typically diagnose 30-50% of patients tested. Recent studies have found that OGM with Saphyr is concordant with CMA and KT and also diagnoses a significant fraction (18-25%) of the patients who could not be diagnosed with traditional methods.

Bionano Customer Praxis Genomics Accredited by College of American Pathologists, Completing First LDT in US for Constitutional Genetic Disorders that Uses Whole Genome Analysis with Saphyr as Alternative to Chromosomal Microarray and Karyotyping

SAN DIEGO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study by the Human Genome Structural Variation Consortium (HGSVC) revealing that their sequencing method based on PacBio HiFi reads detected only 72% of the large SVs that Bionano's optical genome mapping (OGM) detected across 32 different human genomes. The consortium developed its custom sequencing method by combining sequencing with PacBio and the single-strand prep and sequencing method StrandSeq to establish a comprehensive catalog of human SVs with base-pair and haplotype resolution. The cost of this method is estimated, based on list pricing, to be between $10,000 and $20,000 per genome. OGM with Saphyr, which costs less than $500 per genome, was shown to be significantly more sensitive than the sequencing method.

Publication Reveals in Side-by-Side Comparison that Method Using PacBio Sequencing Detects Only 72% of the Large Structural Variants Detected by Optical Genome Mapping with Saphyr

SAN DIEGO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its Saphyr System for optical genome mapping is being introduced as a novel diagnostic tool for heme malignancies by Dr. Rashmi Kanagal-Shamanna of the MD Anderson Cancer Center at the Annual Meeting of the American Society of Hematology (ASH). With more than 18,000 members from nearly 100 countries, the ASH is the world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. The annual meeting is being held virtually at hematology.org from December 5-8.

Bionano Genomics Users Present the Saphyr System As a Novel Diagnostic Tool for Hematological Malignancies at ASH 2020

SAN DIEGO, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the performance and application of its Saphyr system for optical genome mapping are being showcased at the Annual Meeting of the Association for Molecular Pathology (AMP), being held virtually at amp20.amp.org from November 16-20. AMP is widely recognized as the preeminent scientific society dedicated to advancing the clinical practice, science and excellence of molecular and genomic laboratory medicine. With over 2,500 members in over 50 countries working in the field of molecular pathology, its annual meeting is considered the prime event for presenting advances and technological innovations in molecular diagnostics to pathologists, laboratory directors and clinical professionals.

Bionano Genomics and its Users Present the Saphyr System for Optical Genome Mapping and Various Advancements in Clinical Variant Detection at AMP 2020

Company to host conference call today, November 12, at 4:30 pm ET Company to host conference call today, November 12, at 4:30 pm ET

Bionano Genomics Reports Third Quarter 2020 Financial Results and Provides Business Update

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study led by cytogenetics experts from the nation's top clinical and cancer centers in which they recommended that optical genome mapping (OGM) using Bionano's Saphyr System be considered as a first-line test for detection and identification of clinically relevant structural variants and copy number variants in leukemias. The paper, published this week in medRxiv, describes detection and identification of structural variants and copy number variants in 100 patients with acute myeloid leukemia (AML). This study is the largest to-date in leukemia for Bionano and the first published study from the United States comparing Bionano's OGM to karyotyping, the current standard of care in leukemia testing.

Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionano's Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Varia

Publication from UCSF shows Bionano's optical genome mapping technology can detect pathogenic variants missed by whole exome sequencing and by chromosomal microarray in patients with rare genetic disorders and may contribute to more patients receiving definitive molecular diagnoses Publication from UCSF shows Bionano's optical genome mapping technology can detect pathogenic variants missed by whole exome sequencing and by chromosomal microarray in patients with rare genetic disorders and may contribute to more patients receiving definitive molecular diagnoses

Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano's Optical Genome Mapping Technology Can Diagnose Significantly More Patients Than Standard of Care Methods Alone

Top researchers present discoveries in cancer predisposition, neurodegenerative diseases, microdeletion syndromes and other genetic disorders made using Bionano's optical genome mapping technology Top researchers present discoveries in cancer predisposition, neurodegenerative diseases, microdeletion syndromes and other genetic disorders made using Bionano's optical genome mapping technology

Prowess of Bionano Genomics' Saphyr System in Uncovering Novel Genetic Variations That Cause Cancer and Genetic Disease in Full Display at ASHG 2020

Recent publication shows Saphyr’s unique capability in resolving extremely complex structural variants that can cause common genetic disorders called microdeletion syndromes Recent publication shows Saphyr’s unique capability in resolving extremely complex structural variants that can cause common genetic disorders called microdeletion syndromes

Bionano Genomics' Saphyr System Shown to be Indispensable for the Analysis of Certain Genetic Disease Causing Variants

The genomes of at least 20 patients with Multisystem Inflammatory Syndrome in Children and unaffected controls to be analyzed on Saphyr at Boston Children’s Hospital The genomes of at least 20 patients with Multisystem Inflammatory Syndrome in Children and unaffected controls to be analyzed on Saphyr at Boston Children’s Hospital

Boston Children’s Hospital Is Using Bionano’s Saphyr To Study Children With Severe COVID-19 Disease

Stockholders voted in favor of proxy proposal to increase the authorized share count Stockholders voted in favor of proxy proposal to increase the authorized share count

Bionano Genomics Announces Positive Outcome of Its Special Stockholder Meeting

Leading hospitals in Slovenia and Australia adopt Saphyr to improve the diagnosis and treatment of leukemias Leading hospitals in Slovenia and Australia adopt Saphyr to improve the diagnosis and treatment of leukemias

Bionano Genomics Announces Continued Expansion of Global Business with Adoption of Saphyr for Next-Generation Cytogenomics in Eastern Europe and Australia

First official European accreditation of Saphyr-based laboratory developed test helps pave the way for broader adoption of Saphyr for clinical diagnostics applications First official European accreditation of Saphyr-based laboratory developed test helps pave the way for broader adoption of Saphyr for clinical diagnostics applications

German Accreditation of Laboratory Developed Tests on Bionano’s Saphyr System Accelerates Utilization in Clinical Diagnostics

SAN DIEGO, Sept.  17, 2020  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that teams from the Mayo Clinic and from the University of Florida have separately released results generated with Saphyr relating to Amyotrophic Lateral Sclerosis (ALS) and Myotonic Dystrophy (DM), respectively, two severe genetic disorders caused by the expansion of repetitive sequences in the genome. Saphyr identified repeat expansions in patients with ALS and DM that were so large that only Saphyr is capable of sizing them correctly. These findings help increase understanding of the disease-causing mechanisms and may lead to better diagnostic tests, support direct drug development and facilitate better identification of patients who are likely to respond to treatment.

News for Bionano Genomics Stock (BNGO)